Q. Based on the results of IMPRESS trail in NSCLC, which of the following is true :
A. NSCLC with EGFR MUTATION were studied and after progression on gefitinib the trail arm that used gefitinib and chemotherapy combination showed similar PFS as the arm that used chemotherapy alone
B. NSCLC with EGFR MUTATION were studied and after progression on gefitinib the trail arm that used gefitinib and chemotherapy combination showed similar OS as the arm that used chemotherapy alone
C. NSCLC with EGFR MUTATION were studied and after progression on gefitinib the trail arm that used gefitinib and chemotherapy combination showed lesser PFS as the arm that used chemotherapy alone
D. NSCLC with EGFR MUTATION were studied and after progression on gefitinib the trail arm that used gefitinib and chemotherapy combination showed superior PFS but same OS as the arm that used chemotherapy alone Answer: NSCLC with EGFR MUTATION were studied and after progression on gefitinib the trail arm that used gefitinib and chemotherapy combination showed similar PFS as the arm that used chemotherapy alone
